Document:

Fifth Amendment to Patent License Agreement

 Exhibit 10.14 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 FIFTH AMENDMENT 
 This Amendment with the Effective Date of December 15, 2000 is to
the License Agreement dated May 9, 1996 between Sangamo BioSciences, Inc. and Massachusetts Institute of Technology, which was amended on December 10, 1997, December 2, 1998, September 1, 1999 and February 10, 2000.

 The parties thereto now further agree as follows: 
  

	1.	M.I.T. Case No. 8775H, U.S. 60/204,509, filed May 5, 2000, “A Bacterial Two-Hybrid Selection System for Studying Protein-DNA and Protein-Protein
Interactions” by J. Keith Joung, Jeffrey C. Miller and Carl O. Pabo shall be added to the PATENT RIGHTS. The license granted hereunder shall be exclusive in the field of “Selection and identification of nucleic acid-protein
interaction partners in bacteria”. M.I.T. additionally grants COMPANY a non-exclusive Option to PATENT RIGHTS in the field of “Selection and identification of protein-protein interaction partners in bacteria”. Such Option shall expire
January 1, 2003, unless exercised sooner by written notice by an authorized representative of LICENSEE, at which time a payment of [***] dollars ($[***]) will be due and payable to M.I.T. 

  

	2.	Article 1. Definitions. 1.3 “LICENSED PRODUCTS” shall be amended to include the following additional language: 

 and; 
 any product,
compound or derivative thereof that, in the absence of the use of PATENT RIGHTS relating to M.I.T. Case No. 8775H would not have been discovered, identified, selected or determined to have biological activity or utility for commercial use
(hereinafter “IDENTIFIED PRODUCTS”). 
  

	3.	In consideration of the license granted hereunder 

 (a) LICENSEE shall pay M.I.T. an Amendment Issue Fee of $[***], payable as follows: 
  

	 	(i)	[***] dollars ($[***]) due upon signing; and 

  

	 	(ii)	[***] dollars ($[***]) due upon the issuance of the first of the protein-DNA claims in PATENT RIGHTS. 

  

	 	(b)	The License Maintenance Fees due under Paragraph 4.1(b) shall be increased as follows: 

  

	 	(i)	 [***] dollars ($[***]) shall be added to the existing License Maintenance Fee of $[***] so that $[***] per year will cover
the first five Amendments

  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

	 	 
to the License Agreement and will be due on January 1, 2002 and each January 1 thereafter until the January 1 following the issuance of the first protein DNA claims; and

  

	 	(ii)	[***] dollars ($[***]) per year beginning the January 1 following the issuance of the first of the protein-DNA claims and every January 1
thereafter. 

 (c) For sublicenses granted to M.I.T. Case No. 8775H, the Sublicense Issue Fees due under
Paragraph 4.1(h) shall be [***] dollars ($[***]) per sublicense and the Sublicense Maintenance Fees shall be [***] dollars ($[***]) per sublicense. 
 (d) LICENSEE shall be responsible for payment of seventy-five percent (75%) of all fees and costs relating to the U.S. filing,
prosecution and maintenance of M.I.T. Case No. 8775H and 100% of all fees and costs relating to foreign filing prosecution and maintenance of Case No. 8775H whether such fees and costs were incurred before or after the effective date of
this Amendment. In the case of any divisionals, continuations, continuation-in-part applications to the extent the claims are directed to subject matter specifically described in M.I.T. Case No. 8775H and confined solely to claims involving
protein-DNA interactions (exclusive field in Section 3(a)(i) above), LICENSEE shall have the primary responsibility for filing, prosecution and maintenance of such patent applications. LICENSEE shall seek broad claims in prosecuting such
claims, with M.I.T.’s review and approval, such approval not to be unreasonably withheld. LICENSEE shall provide guidance to patent counsel on prosecution matters, with ultimate decisionmaking authority resting with M.I.T. In the case of
foreign filings, LICENSEE shall have the right to determine in which territories it will file, and inform M.I.T. on a timely basis of such decisions. If LICENSEE elects to drop coverage in a country or countries, it shall inform M.I.T. on a timely
basis, and M.I.T. at its sole discretion may assume these costs. LICENSEE shall receive copies of all documents relating to the U.S. or foreign filing, prosecution and maintenance of M.I.T. Case No. 8775H and all derivative patents and patent
applications. 
 (e) Paragraph 4.1(c) shall be amended to read in its entirety Running Royalties in an amount equal to
[***] Percent ([***]%) of NET SALES of the LICENSED PRODUCTS and LICENSED PROCESSES used, leased or sold by and/or for LICENSEE and/or its sublicensees, except that if the PATENT RIGHTS of only case 8775H cover the LICENSED
PRODUCT then: 
 (f) Running Royalties due under Paragraph 4.1(c), shall be as follows: 
  

	 	(i)	If the claims of the PATENT RIGHTS of M.I.T. Case No. 8775H cover the composition of matter of a LICENSED PRODUCT, Running Royalties in an amount equal to
[***] Percent ([***]%) of NET SALES of the LICENSED PRODUCTS and LICENSED PROCESSES used, leased or sold by and/or for LICENSEE and/or its sublicensees, shall be due; 

  

	 	(ii)	 If the product sold by and/or for LICENSEE and/or its sublicensees is an IDENTIFIED PRODUCT, then Running Royalties in an amount equal to [***]
Percent ([***]%) of NET SALES of IDENTIFIED PRODUCT used, leased or sold by and/or for LICENSEE and/or its sublicensees, shall

  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

	 	 
be due. These Running Royalties shall be in effect for the ten (10) years from the first commercial sale of an IDENTIFIED PRODUCT, and this obligation shall survive termination of this
agreement. 

 All other terms and conditions as set forth in the Agreement. 
 Agreed to for: 
  

									
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 		 	SANGAMO BIOSCIENCES, INC.
					
	By:	 	 /s/ Lita Nelson
	 		 	By:	 	 /s/ Peter Bluford

					
	Name:	 	 Lita L. Nelson
	 		 	Name:	 	 Peter Bluford

					
	Title:	 	 Director, Technologic Licensing Office
	 		 	Title:	 	 Vice President, Corporate Development

					
	Date:	 	 January 11, 2001
	 		 	Date:	 	 December 18, 2000Sixth Amendment to Patent License Agreement

 Exhibit 10.17 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 SIXTH AMENDMENT TO PATENT LICENSE AGREEMENT 
 THIS SIXTH AMENDMENT TO
PATENT LICENSE AGREEMENT (the “Amendment”) is made and entered into effective as of September 1, 2005 (the “Amendment Effective Date”), by and between Massachusetts Institute of Technology, a Massachusetts
corporation (“M.I.T.”), and Sangamo BioSciences, Inc., a Delaware corporation (“Sangamo”) having principal offices at 501 Canal Blvd, Suite A100, Richmond, CA 94804. 
 M.I.T. and Sangamo hereby agree to amend that certain Patent License Agreement, dated May 9, 1996, as previously amended (the
“Agreement”) as follows: 
 1. Definitions. All defined terms used and not otherwise defined in this Amendment
have the meanings ascribed to such terms in the Agreement. For the purpose of this Amendment, the following terms, when capitalized, have the following meanings: 
 (a) “Agricultural Field” means the use of zinc finger proteins in a vascular and non-vascular plant or plant cell to modify (a) the genome of such plant or plant cell or
(b) the nucleic acid or protein expression of such plant or plant cell. For the purpose of this Amendment, “non-vascular” plants shall include algae and fungi (excluding yeast). 
 (b) “Agricultural Product” means any Licensed Product in the Agricultural Field, Licensed Process in the
Agricultural Field, and/or product discovered or developed through the use of Licensed Product(s) or Licensed Process(es) in the Agricultural Field. 
 (c) “Royalty Income” means any consideration paid to Sangamo that constitutes a running royalty paid by a Sublicensee on its sales of an Agricultural Product. 
 (d) “Sublicensee” means any sublicensee of Sangamo (or any further downstream sublicensees thereof) under the Patent
Rights. 
 2. Field. For clarity, the Fields of Use shall include the Agricultural Field. 
 3. Financial Terms. Notwithstanding the terms and conditions of the Agreement (including without limitation Article 4 thereof),
Sangamo’s sole financial obligation to M.I.T. with respect to (x) the grant of sublicenses under the Patent Rights in the Agricultural Field to Sublicensees and (y) the exploitation of the Patent Rights in the Agricultural Field by
Sangamo and/or Sublicensees, including the development and commercialization of Agricultural Products, shall be as follows: 
 (a) Subject to subsection (b) below, Sangamo shall pay M.I.T. [***] percent ([***]%) of all Royalty Income received by Sangamo from Sublicensees. Such payments shall be due sixty (60) days after the end of the
quarter in which Sangamo receives such Royalty Income and shall accompany the report contemplated by Section 5.2 of the Agreement. 
  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 (b) Sangamo may deduct, from the amount otherwise due to M.I.T. pursuant to
subsection (a) above, an amount equal to [***] percent ([***]%) of all payments made by Sangamo to third party licensors on account of sales of Agricultural Products by Sublicensees, provided that the amount paid to M.I.T. as a
result of such deduction shall not be less than (i) [***] percent ([***]%) of all Royalty Income received by Sangamo from Sublicensees and (ii) [***] percent ([***]%) of all payments made by Sangamo to third
party licensors on account of sales of Agricultural Products by Sublicensees. For clarity, the foregoing subsection (ii) shall not be interpreted as requiring Sangamo to pay M.I.T. more than [***] percent ([***]%) of all Royalty
Income received by Sangamo from Sublicensees, even in circumstances where [***] percent ([***]%) of all Royalty Income is less than [***] percent ([***]%) of all payments made by Sangamo to third party licensors on
account of sales of Agricultural Products by Sublicensees. 
 (c) The following are examples of the application of
subsections (a) and (b) above: 
 (i) Sangamo receives $[***] in Royalty Income from Sublicensees and
pays third party licensors a total of $[***] on account of the sales of Agricultural Products by Sublicensees. Absent such third party licensor payment obligations, Sangamo would owe M.I.T. $[***] on account of such Royalty Income.
Pursuant to subsection (b) above, Sangamo may deduct $[***] (i.e., [***]% of $[***]) from the $[***] it would otherwise owe M.I.T., but since such deduction would result in a payment to M.I.T. of $[***] and
$[***] is less than $[***] (i.e., [***]% of $[***]), Sangamo needs to pay M.I.T. $[***] to satisfy subsection (b)(i) above. Since $[***] is more than [***]% of $[***], no further
adjustment is necessary to satisfy subsection (b)(ii) above. Result: Sangamo shall pay M.I.T. $[***]. 
 (ii)
Sangamo receives $[***] in Royalty Income from Sublicensees and pays third party licensors a total of $[***] on account of the sales of Agricultural Products by Sublicensees. Absent such third party licensor payment obligations,
Sangamo would owe M.I.T. $[***] on account of such Royalty Income. Pursuant to subsection (b) above, Sangamo may deduct $[***] (i.e., [***]% of $[***]) from the $[***] it would otherwise owe M.I.T., but since
such deduction would result in a payment to M.I.T. of $[***] and $[***] is less than $[***] (i.e., [***]% of $[***]), Sangamo needs to pay M.I.T. $[***] to satisfy subsection (b)(i) above. Since
$[***] is less than [***]% of $[***], a further adjustment to $[***] is necessary to satisfy subsection (b)(ii) above. Result: Sangamo shall pay M.I.T. $[***]. 
 4. Miscellaneous. This Amendment amends the terms of Agreement as expressly provided above, and the Agreement, as so amended and including all
of its other terms and provisions that are not amended, remains in full force and effect. This Amendment may be executed in counterparts and by facsimile. 
  

 2 
  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 IN WITNESS WHEREOF, the parties hereto have caused this Sixth Amendment to Patent
License Agreement to be executed by their duly authorized representatives as of the date first above written. 
  

			
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY
		
	By:	 	 /s/ Lita Nelsen

		
	Name:	 	 Lita L. Nelsen

		
	Title:	 	 Director, Technology Licensing Office

	
	SANGAMO BIOSCIENCES, INC.
		
	By:	 	 /s/ David G. Ichikawa

		
	Name:	 	 David G. Ichikawa

		
	Title:	 	 SVP Business Development

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]